Law & Policy

·

News

Cybin Gets U.S. Patent for Psilocybin-Like Depression Drug

Cybin Gets U.S. Patent for Psilocybin-Like Depression Drug

What they found

Cybin received a U.S. patent covering its psilocybin analog program CYB003 for major depressive disorder.

Cybin received a U.S. patent covering its psilocybin analog program CYB003 for major depressive disorder.

How solid is it?

n/a

n/a

Not a study

Not a study

Evidence ladder: Lab dish → Animal → Early human → Strong human. Reviews summarize earlier research.

At a glance

Latin name

Compound

CYB003 (psilocybin analog)

CYB003 (psilocybin analog)

Published in

investing.com

investing.com

Covered in Shroom Scan

Section

Psychedelic news

Psychedelic news

As it ran in Shroom Scan

Shroom Stocks

Shroom Stocks

Biopharmaceutical company Cybin Inc. received a U.S. patent for compositions created through its psilocybin analog program, CYB003, which aims to treat Major Depressive Disorder.

Biopharmaceutical company Cybin Inc. received a U.S. patent for compositions created through its psilocybin analog program, CYB003, which aims to treat Major Depressive Disorder.

New edible mushroom discovered in Mexico

Read the original study ↗

Get Shroom Scan

Next study

Psilocybin Rarely Leads to Emergency Care, Large Survey Finds ›

Shroom Scan · Every Friday

Get Studies Like This, Translated, Every Week

Ten new studies a week, each boiled down to what it found and why it matters to you. Free, and one click to leave.

See what's inside →